AKAN Akanda Corp. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AKAN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$1.5
52W High
$46.45
52W Low
$1.19
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$3.03M
P/E
0.01
ROE
-60.9%
Profit margin
-266.3%
Debt/Equity
0.12
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
95%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals critical weaknesses in Akanda Corp.'s financial health, with a Piotroski F-Score of just 3/9 indicating severe operational and profitability deterioration. Despite a low Price/Book ratio of 0.07 and a defensive Graham fair value of $281.01, the company trades at $1.50 due to catastrophic profitability metrics, including a -266.31% profit margin and -443.84% operating margin. The absence of Altman Z-Score data is concerning, but the Piotroski score below 4 strongly signals financial distress. Combined with a 5-year price decline of 100%, lack of analyst coverage, and negative insider sentiment, the stock exhibits deep structural issues.
Key Strengths
Extremely low Price/Book ratio (0.07) suggests potential value if turnaround occurs
Low Debt/Equity ratio (0.12) indicates minimal leverage risk
Current Ratio of 1.25 shows short-term liquidity is technically sufficient
Graham Number ($281.01) implies massive upside potential if fundamentals stabilize
Recent 1-week price surge (+18.1%) may indicate speculative interest or short-term catalyst
Key Risks
Piotroski F-Score of 3/9 signals high risk of financial distress and poor earnings quality
Profit Margin of -266.31% and Operating Margin of -443.84% reflect unsustainable operations
ROE of -60.86% and ROA of -28.89% indicate severe capital inefficiency
Market cap and key financials listed as 'N/A' suggest possible delisting, data inaccuracy, or corporate restructuring
5-year price return of -100% implies total shareholder value destruction
AI Fair Value Estimate
Based on comprehensive analysis
$281.01
+18634.0% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
12
Weak
35
10
5
12
0
AI Verdict
Extreme financial distress with negligible investor confidence
Key drivers: Piotroski F-Score of 3, Negative profitability across all margins, Total shareholder value loss over 5 years, No analyst coverage, Missing Altman Z-Score and key financials
Confidence
96%
Value
35/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.07 is deeply discounted
- Graham Number implies significant theoretical value
Watchpoints
- P/E of 0.01 is nonsensical due to negative earnings
- Price/Sales of 3.62 is high for a money-losing company
- No meaningful valuation multiples due to financial instability
Future
10/100
Ref Growth rates
Positives
No standout positives identified.
Watchpoints
- No available growth data (YoY or Q/Q)
- No analyst target prices or growth estimates
- Negative operating trends suggest no near-term recovery
Past
5/100
Ref Historical trends
Positives
- 52-week low of $1.19 suggests potential bottoming
Watchpoints
- 5-year change of -100.0%
- 1-year change of -94.2%
- 6-month change of -92.4%
- No 50-day or 200-day moving averages available
Health
12/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 0.12 is very low
- Current Ratio of 1.25 meets minimum threshold
Watchpoints
- Piotroski F-Score of 3/9 indicates weak financial health
- Quick Ratio of 0.89 < 1.0 signals liquidity pressure
- ROE and ROA deeply negative
- Altman Z-Score missing — potential red flag
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
- No ex-dividend date
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.5
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AKAN and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AKAN
Akanda Corp.
Primary
|
-100.0% | -99.9% | -94.2% | -92.4% | -40.2% | +18.1% |
|
ACON
Aclarion, Inc.
Peer
|
-100.0% | -100.0% | -98.2% | -65.2% | -34.0% | -1.6% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
ADTX
Aditxt, Inc.
Peer
|
-100.0% | -100.0% | -100.0% | -99.6% | -65.3% | -17.8% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
0.01
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
0.07
P/S Ratio
3.62
EV/Revenue
-2.29
EV/EBITDA
0.52
Market Cap
$3.03M
Profitability
Profit margins and return metrics
Profit Margin
-266.31%
Operating Margin
-443.84%
Gross Margin
24.91%
ROE
-60.86%
ROA
-28.69%
Growth
Revenue and earnings growth rates
Revenue Growth
N/A
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.12
Low debt
Current Ratio
1.25
Good
Quick Ratio
0.89
Poor
Cash/Share
$17.33
Healthcare Sector Comparison
Comparing AKAN against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
P/E Ratio
0.01
This Stock
vs
197.75
Sector Avg
-100.0%
(Discount)
Return on Equity (ROE)
-60.86%
This Stock
vs
-56.86%
Sector Avg
+7.0%
(Above Avg)
Profit Margin
-266.31%
This Stock
vs
-20.8%
Sector Avg
+1180.5%
(Superior)
Debt to Equity
0.12
This Stock
vs
2.68
Sector Avg
-95.6%
(Less Debt)
Current Ratio
1.25
This Stock
vs
3.45
Sector Avg
-63.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AKAN
Akanda Corp.
|
BEARISH | $3.03M | 0.01 | -60.9% | -266.3% | $1.5 | |
|
ACON
Aclarion, Inc.
|
BEARISH | $2.68M | - | -97.7% | -% | $2.54 | |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | |
|
ADTX
Aditxt, Inc.
|
BEARISH | $0.9M | - | -% | -% | $0.51 | |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 |
Past News Coverage
Recent headlines mentioning AKAN from our newsroom.
Newest → oldest
No matching news yet.